BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35731052)

  • 1. Retrospective analysis of risk factors for bone metastasis in newly diagnosed prostate cancer patients.
    Peng C; Juan C; Mao W; Jinghe Y; Renli T
    Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):3832-3839. PubMed ID: 35731052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors of bone metastasis in patients with newly diagnosed prostate cancer.
    Chaoying L; Chao M; Xiangrui Y; Yingjian H; Gang Z; Yunhan R; Yu G
    Eur Rev Med Pharmacol Sci; 2022 Jan; 26(2):391-398. PubMed ID: 35113414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing a prediction model for prostate cancer bone metastasis.
    Chen S; Wang L; Qian K; Jiang W; Deng H; Zhou Q; Wang G; Liu X; Wu CL; Xiao Y; Wang X
    Int J Biol Sci; 2019; 15(1):208-220. PubMed ID: 30662360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Single-center study of the abnormal concentration of bone imaging agent and prostate cancer bone metastasis prediction model].
    Cheng Y; Luo LP; Hu S; Li LN; Wu C; Wu B; Wang DW
    Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):876-881. PubMed ID: 33113631
    [No Abstract]   [Full Text] [Related]  

  • 5. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.
    Chang CC; Lee YC; Tsai HW; Yii SC; Yen TH; Chu FY
    Asian Pac J Cancer Prev; 2015; 16(13):5261-4. PubMed ID: 26225663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Predictive factors for bone metastases of prostate cancer].
    Chen YH; Nie P; Jiang W; Zhao SJ; Zhang Z; Lin HX; Li MY; Liu YQ; Li PH; Zhu XS
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Feb; 36(2):205-9. PubMed ID: 26922017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma.
    Chen Y; Lin Y; Nie P; Jiang W; Liu Y; Yuan R; Li M; Zhao S; Lin H; Li P; Zhang J; Hu Z; Xu J; Zhu X
    Med Sci Monit; 2017 Apr; 23():1768-1774. PubMed ID: 28400549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
    Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Factors Influencing Bone Metastasis in Prostate Cancer and Diagnostic Value of Serum PSA, CysC and D-D.
    Liu X; Zhao C; Lin J; Liu B
    Arch Esp Urol; 2024 Jan; 77(1):72-78. PubMed ID: 38374016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical association between coagulation indexes, platelet-related parameters, and bone metastasis of newly diagnosed prostate cancer.
    Yu Z; Yuan M; Chen G
    Eur J Med Res; 2023 Dec; 28(1):587. PubMed ID: 38093347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic effectiveness of serum sialic acid predicts both qualitative and quantitative prostate cancer in patients with prostate-specific antigen between 4 and 20 ng/mL.
    Sun J; Yan L
    Front Endocrinol (Lausanne); 2023; 14():1188944. PubMed ID: 37645415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients.
    Xie GS; Li G; Li Y; Pu JX; Huang YH; Li JH; Yin HM
    Chin Med J (Engl); 2019 Nov; 132(22):2684-2689. PubMed ID: 31725446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical value of serum isoform [-2] proprostate-specific antigen and its derivatives in predicting aggressive prostate cancer].
    Sun KX; Yan CL; Li ZY; Liu P; Zhang W; He Q
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):234-239. PubMed ID: 32306004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer.
    Sun J; Tian T; Wang N; Jing X; Qiu L; Cui H; Liu Z; Liu J; Yan L; Li D
    Front Endocrinol (Lausanne); 2024; 15():1338420. PubMed ID: 38384968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer.
    Narayan P; Fournier G; Gajendran V; Leidich R; Lo R; Wolf JS; Jacob G; Nicolaisen G; Palmer K; Freiha F
    Urology; 1994 Oct; 44(4):519-24. PubMed ID: 7524237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
    Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
    Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.